VivoSeq
Dermatology

Rosacea

54

Pipeline Programs↗

6

Active Trials↗

29

Companies Involved↗

Rosacea is a moderately active landscape with 54 programs across 29 companies. The most active players are Guizhou Bailing Group Pharmaceutical Co Ltd, Tarsus Pharmaceuticals, Inc., Dermata Therapeutics. 12 therapies are approved with 9 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

61/100

Pipeline Velocity

11/100

Mech. Concentration

10/100

Completion Rate

88/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Guizhou Bailing Group Pharmaceutical Co Ltd

1 program

Phase 1T

Tarsus Pharmaceuticals, Inc.

2 programs

Phase 2D

Dermata Therapeutics

2 programs

Phase 2Amgen logo

Amgen

2 programs

Phase 2AstraZeneca logo

AstraZeneca

2 programs

Phase 2A

AiViva BioPharma, Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical5

Zinc Sulfate

Fakultas Kedokteran Universitas Indonesia

Brimonidine Tartrate

AbbVie

Sumatriptan Succinate

GSK

Botulinum Toxin Type a

Revance Therapeutics, Inc.

Metronidazole Lotion

LEO Pharma

Phase 15

Secukinumab

Novartis

Trametinib

Novartis

Timolol

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Calcium Dobesilate

Guizhou Bailing Group Pharmaceutical Co Ltd

CLS001

Maruho Co., Ltd.

Phase 223

Rifaximin

Salix

Deucravacitinib

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Erenumab

Amgen

Roflumilast

AstraZeneca

Amitriptyline

AstraZeneca

Phase 39

Isotretinoin

Conrado Roberto Hoffmann Filho

Ivermectin

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Doxycycline Hyclate

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Generic Ingenol Mebutate

Actavis Inc.

Finacea

Actavis Inc.

Approved12

Tretinoin

Valeant Pharmaceuticals

Brimonidine

Novartis

Minocycline

Triax

Dapsone

Almirall, S.A.

Metronidazole

DePuy Orthopaedics

Analysis

Modality Breakdown

98%

Small molecule

83 of 85 classified programs — the dominant modality here.

2%ALL OTHERSMonoclonal antibody22%

Small molecule leads; the ring shows all 85 classified programs, each share of the total. Modality classified for 98% of 88 pipeline programs.

Analysis

Trial Status

104

clinical trials

Completed81 · 78%
Withdrawn6 · 6%
Unknown status6 · 6%
Terminated4 · 4%
Enrolling by invitation3 · 3%
Recruiting2 · 2%
Other2 · 2%

Clinical Trials

Trial Activity

104 trials

Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea
Recruiting·WWright State University·Phase 2·NCT06312813·48 enrolled
Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea
Recruiting·NNarrows Institute for Biomedical Research·Phase 2·NCT06952517·20 enrolled
Analysis of the Microbiome in Rosacea
Active, not recruiting·JJohns Hopkins University·Phase 1·NCT04108897·150 enrolled
Efficacy and Safety of Tranilast Combined With Minocycline in the Treatment of Rosacea
Enrolling by invitation·SSecond Affiliated Hospital of Xi'an Jiaotong University·Phase 4·NCT06307288·45 enrolled
Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)
Enrolling by invitation·TTarsus Pharmaceuticals, Inc.·Phase 2·NCT07443202·155 enrolled
Real-World Study of Cligabalin(HSK16149) for the Treatment of Rosacea
Enrolling by invitation·TThe First Affiliated Hospital with Nanjing Medical University·Preclinical·NCT07606820·60 enrolled
A Safety and Efficacy Study of DRM02 in Subjects With Rosacea
Completed·DDermira, Inc.·Phase 2·NCT01993446·30 enrolled
Bioequivalence Study of Ivermectin Cream 1% in Treatment of Moderate to Severe Facial Rosacea
Completed·ZZydus Worldwide DMCC·Phase 3·NCT04106726·525 enrolled
A Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Rosacea
Completed·AAOBiome LLC·Phase 2·NCT03590366·140 enrolled
RosaC-RF : Bipolar Radiofrequency vs Doxycycline in Rosacea
Completed·—·N/A·NCT02204254·20 enrolled
A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea
Completed·VVyne Therapeutics Inc.·Phase 3·NCT04608500·771 enrolled
A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Rosacea
Completed·AAmorepacific Corporation·Phase 2·NCT02583009·216 enrolled
A Pilot Study on the Use of Seysara for Rosacea
Completed·DDerm Research, PLLC·Phase 4·NCT04555525·100 enrolled
A Twelve Week Safety and Efficacy Study in Rosacea
Completed·MMaruho Co., Ltd.·Phase 2·NCT01784133·240 enrolled
Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea
Completed·PPadagis LLC·Phase 3·NCT02795117·486 enrolled
Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)